Carbapenems

Journal of Chemotherapy

Volumn 25, Issue 1, 2013, Pages 1-17

  Breilh, Dominique ^a   Texier Maugein, Jeannette ^a   Allaouchiche, Bernard ^b   Saux, Marie Claude ^a   Boselli, Emmanuel ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PENICILLIN BINDING PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER; ANAEROBIC BACTERIUM; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BINDING AFFINITY; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DIABETIC FOOT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; LOWER RESPIRATORY TRACT INFECTION; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTRE TRIAL (TOPIC); PNEUMONIA; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIA; CARBAPENEMS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 84873203344     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000032     Document Type: Review

References (151)

1. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008;9:23-37.
2. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943-60.
3. Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect. 2008;14:1102-11.
4. Slama TG. Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Crit Care. 2008;12:233.
5. Dedhia HV, McKnight R. Doripenem: position in clinical practice. Expert Rev Anti Infect Ther. 2009;7:507-14.
6. Shah PM. Parenteral carbapenems. Clin Microbiol Infect. 2008;14(Suppl 1):175-80.
7. Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia Coli and Pseudomonas Aeruginosa. Antimicrob Agents Chemother. 2008;52:1510-2.
8. Marti S, Sanchez-Cespedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter Baumannii clinical isolates. Int J Antimicrob Agents. 2009;33:181-2.
9. Alvarez-Lerma F, Grau S, Ferrandez O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des Devel Ther. 2009;3:173-90.
10. Zhao WH, Chen G, Ito R, Hu ZQ. Relevance of resistance levels to carbapenems and integron-borne blaimp-1, blaimp-7, blaimp-10 and blavim-2 in clinical isolates of Pseudomonas Aeruginosa. J Med Microbiol. 2009;58:1080-5.
11. Chen L, Mediavilla JR, Endimiani A, Rosenthal ME, Zhao Y, Bonomo RA, et al. Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (Bla Kpc) variants. J Clin Microbiol 2011;49:579-85.
12. Kim JY, Jung HI, An YJ, Lee JH, Kim SJ, Jeong SH, et al. Structural basis for the extended substrate spectrum of Cmy-10, a plasmid-encoded class C B-lactamase. Mol Microbiol. 2006;60:907-16.
13. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against pseudomonas aeruginosa expressing Mexa-Mexb-Oprm efflux pumps. Diagn Microbiol Infect Dis. 2007;57:153-61.
14. Queenan AM, Bush K. Carbapenemases: the versatile B-lactamases. Clin Microbiol Rev. 2007;20:440-58.
15. Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18:413-31.
16. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (meropenem yearly susceptibility test information collection) 2006 results. Diagn Microbiol Infect Dis. 2008;60:185-92.
17. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of Carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas Aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo). 2006;59:220-8.
18. Burgess DS, Hall RG, 2nd. In vitro killing of parenteral B-lactams against standard and high inocula of extended-spectrum B-lactamase and non-Esbl producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2004;49:41-6.
19. Credito KL, Ednie LM, Appelbaum PC. Comparative antianaerobic activities of doripenem determined by mic and time-kill analysis. Antimicrob Agents Chemother. 2008;52:365-73.
20. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54:144-54.
21. Tsuji M, Matsuda H, Miwa H, Miyazaki S. Antimicrobial-induced release of endotoxin from Pseudomonas Aeruginosa: comparison of in vitro and animal models. J Antimicrob Chemother. 2003;51:353-9.
22. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. Bactericidal activities of meropenem and ertapenem against extended-spectrum-B-lactamase-producing Escherichia Coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother. 2007;51:1481-6.
23. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39:185-201.
24. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl. 1995;96:11-6.
25. Keam SJ. Doripenem: A review of its use in the treatment of bacterial infections. Drugs. 2008;68:2021-57.
26. Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother. 2002; 46:3506-11.
27. Lister PD. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther. 2007;5:793-809.
28. Drusano GL, Standiford HC, Bustamante C, Forrest A, Rivera G, Leslie J, et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 1984; 26:715-21.
29. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, et al. Ertapenem in critically Ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother. 2007;59:277-84.
30. Wong BK, Sahly Y, Mistry G, Waldman S, Musson D, Majumdar A, et al. Comparative disposition of [14c]Ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica. 2004;34:379-89.
31. Cirillo I, Mannens G, Janssen C, Vermeir M, Cuyckens F, Desai-Krieger D, et al. Disposition, metabolism, and excretion of [14c]Doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother. 2008;52:3478-83.
32. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027-52.
33. Condon RE, Walker AP, Hanna CB, Greenberg RN, Broom A, Pitkin D. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin Infect Dis. 1997;24(Suppl 2):S181-3.
34. Drusano GL. An overview of the pharmacology of imipenem/cilastatin. J Antimicrob Chemother. 1986;18(Suppl E):79-92.
35. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis. 1993;21:172-9.
36. Tegeder I, Bremer F, Oelkers R, Schobel H, Schuttler J, Brune K, et al. Pharmacokinetics of imipenem-cilastatin in critically Ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1997;41:2640-5.
37. Thalhammer F, Horl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet. 2000;39:271-9.
38. Mistry GC, Majumdar AK, Swan S, Sica D, Fisher A, Xu Y, et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J Clin Pharmacol. 2006;46:1128-38.
39. Nix DE, Majumdar AK, Dinubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53(Suppl 2):23-8.
40. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46.
41. Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, et al. Multicenter randomized trial comparing meropenem (1.5 G Daily) and imipenem/ cilastatin (2 G Daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res. 1999;25:243-52.
42. Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J Chemother. 2002;14:609-17.
43. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002;34:1076-83.
44. Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther. 2002;24:1770-85.
45. Hartenauer U, Weilemann LS, Bodmann KF, Ritzerfeld WW, Asmus S, Koch EM. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect. 1990;15(Suppl A):61-4.
46. Fink MP, Snydman DR, Niederman MS, Leeper KV, Jr, Johnson RH, Heard SO, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994;38:547-57.
47. Torres A, Bauer TT, Leon-Gil C, Castillo F, Alvarez-Lerma F, Martinez-Pellus A, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax. 2000;55:1033-9.
48. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther. 2003;25:485-506.
49. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47:3442-7.
50. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 H for treatment of nosocomial pneumonia. Respir Med. 2006;100:1554-65.
51. Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multi-centre study. Infection. 2006;34:127-34.
52. Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med. 1997;25:1663-70.
53. Alvarez Lerma F. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother. 2001;13:70-81.
54. Bassetti M, Righi E, Fasce R, Molinari MP, Rosso R, Di Biagio A, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum B-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother. 2007;60:433-5.
55. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089-96.
56. Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin. 2008;24:2113-26.
57. Siempos, II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J. 2007;29:548-60.
58. Krilov LR, Blumer JL, Stern RC, Hartstein AI, Iglewski BN, Goldmann DA. Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis. Rev Infect Dis. 1985;7(Suppl 3):S482-9.
59. Pedersen SS, Pressler T, Hoiby N, Bentzon MW, Koch C. Imipenem/cilastatin treatment of multiresistant pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother. 1985;16:629-35.
60. Pedersen SS, Pressler T, Jensen T, Rosdahl VT, Bentzon MW, Hoiby N, et al. Combined imipenem/cilastatin and tobramycin therapy of multiresistant pseudomonas aeruginosa in cystic fibrosis. J Antimicrob Chemother. 1987;19:101-7.
61. Strandvik B, Malmborg AS, Bergan T, Michalsen H, Storrosten OT, Wretlind B. Imipenem/cilastatin, an alternative treatment of Pseudomonas infection in cystic fibrosis. J Antimicrob Chemother. 1988;21:471-80.
62. Byrne S, Maddison J, Connor P, Doughty I, Dodd M, Jenney M, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother. 1995;36(Suppl A):135-43.
63. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest. 2005;128:2336-46.
64. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros. 2008;7:142-6.
65. Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg. 1997;174:284-90.
66. Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg. 2001;233:79-87.
67. Kanellakopoulou K, Giamarellou H, Papadothomakos P, Tsipras H, Chloroyiannis J, Theakou R, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 1993;12:449-53.
68. Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1995;35:139-48.
69. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. J Antimicrob Chemother. 1995;36(Suppl A):191-205.
70. Basoli A, Meli EZ, Mazzocchi P, Speranza V. Imipenem/cilastatin (1.5 G Daily) versus meropenem (3.0 G daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis. 1997;29:503-8.
71. Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, et al. Meropenem (1.5 G/Day) is as effective as imipenem/cilastatin (2 G/Day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents. 1999;11:107-13.
72. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect. 2000;6:294-302.
73. Huizinga WK, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp-Korstanjep JA, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother. 1995;36(Suppl A):179-89.
74. Kempf P, Bauernfeind A, Muller A, Blum J. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection. 1996;24:473-9.
75. Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC, Nichols RL, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis. 1995;21:544-50.
76. Berne TV, Yellin AE, Appleman MD, Heseltine PN, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. J Am Coll Surg. 1996;182:403-7.
77. Wilson SE. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis. 1997;24(Suppl 2):S197-206.
78. Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK. Meta-analysis: ertapenem for complicated intra-abdominal infections. Aliment Pharmacol Ther. 2008;27:919-31.
79. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of Iv doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase iii, prospective, multicenter, randomized, double-blind, non-inferiority study. Clin Ther. 2008;30:868-83.
80. Matsumoto T, Muratani T. Newer carbapenems for urinary tract infections. Int J Antimicrob Agents. 2004;24(Suppl 1):S35-8.
81. Naber KG, Savov O, Salmen HC. Piperacillin 2 G/Tazobactam 0.5 G is as effective as imipenem 0.5 G/cilastatin 0.5 G for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents. 2002;19:95-103.
82. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis. 1995;21:86-92.
83. Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002;60:16-22.
84. Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46:2895-900.
85. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004;53(Suppl 2):67-74.
86. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother. 2009;53:3782-92.
87. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176-89.
88. Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, et al. Ertapenem once daily versus piperacillintazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460-8.
89. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J. 1995;88:397-404.
90. Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt). 2005;6:269-82.
91. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (sidestep): prospective, randomised, controlled, double-blinded, multi-centre trial. Lancet. 2005;366:1695-703.
92. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically Ill patient. Crit Care Med. 2009;37:840-51; quiz 59.
93. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically Ill patients with sepsis. Clin Pharmacokinet. 2005;44:539-49.
94. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10; quiz 1-2.
95. Mouton JW, Vinks AA. Is continuous infusion of B-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996;38:5-15.
96. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012;56:2129-31.
97. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40:219-23.
98. Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically Ill patients. Antimicrob Agents Chemother. 2010;54:2360-4.
99. Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. Clinical isolates from the UK. J Antimicrob Chemother. 2009;63:659-67.
100. Hombach M, Bloemberg GV, Bottger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of gram-negative bacilli. J Antimicrob Chemother. 2012;67:622-32.
101. Mouton JW, Vinks AA. Continuous infusion of B-lactams. Curr Opin Crit Care. 2007;13:598-606.
102. Kiem S, Schentag JJ. Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of anti-biotics for treatment of ventilator-associated pneumonia. Semin Respir Crit Care Med. 2006;27:51-67.
103. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006;222:114-24.
104. Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Overview of seizure-inducing potential of doripenem. Drug Saf. 2009;32:709-16.
105. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther. 2009;31:42-63.
106. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother. 1998;42:94-9.
107. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of ertapenem (Mk-0826) against recent clinical bacteria collected in europe and australia. Antimicrob Agents Chemother. 2001;45:1860-7.
108. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 2005;11:974-84.
109. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother. 2004;48:1384-96.
110. Pelak BA, Woods GL, Teppler H, Friedland I, Bartizal K, Motyl M. Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. J Chemother. 2002;14:227-33.
111. Rhomberg PR, Jones RN, Sader HS, Fritsche TR. Antimicrobial resistance rates and clonality results from the meropenem yearly susceptibility test information collection (Mystic) programme: report of year five (2003). Diagn Microbiol Infect Dis. 2004;49:273-81.
112. Goldstein EJ, Citron DM. Activity of a novel carbapenem, doripenem, against anaerobic pathogens. Diagn Microbiol Infect Dis. 2009;63:447-54.
113. Snydman DR, Jacobus NV, McDermott LA. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob Agents Chemother. 2008;52:4492-6.
114. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized B-lactamases. Antimicrob Agents Chemother. 2004;48:1313-9.
115. Wise R, Donovan IA, Lockley MR, Drumm J, Andrews JM. The pharmacokinetics and tissue penetration of imipenem. J Antimicrob Chemother. 1986;18(Suppl E):93-101.
116. Trudel JL, Wittnich C, Brown RA. Antibiotics bioavailability in acute experimental pancreatitis. J Am Coll Surg. 1994;178:475-9.
117. Benoni G, Cuzzolin L, Bertrand C, Puchetti V, Velo G. Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy. J Antimicrob Chemother. 1987;20:725-8.
118. Benoni G, Cuzzolin L, Bertrand C, Pucchetti V, Velo G. Penetration of imipenem-cilastatin into the lung tissue and pericardial fluid of thoracotomized patients. Chemioterapia. 1987;6(2 Suppl):259-60.
119. Wittmann DH, Kuipers TH, Fock R, Holl M, Bauernfeind A. Bone concentrations of imipenem after a dose of imipenem/cilastatin [in German]. Infection. 1986;14(Suppl 2):S130-7.
120. Naber KG, Adam D, Bauernfeind A, Honig E. Imipenem/cilastatin: In vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections [in German]. Infection. 1986;14(Suppl 2):S122-9.
121. Wise R, Logan M, Cooper M, Ashby JP, Andrews JM. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother. 1990;34:1515-7.
122. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother. 1991;28:911-8.
123. Byl B, Jacobs F, Roucloux I, de Franquen P, Cappello M, Thys JP. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother. 1999;43:681-2.
124. Conte JE, Jr, Golden JA, Kelley MG, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents. 2005;26:449-56.
125. Sano T, Sakurai M, Dohi S, Oyama A, Murota K, Sugiyama H, et al. Investigation of meropenem levels in the human bone marrow blood, bone, joint fluid and joint tissues [in Japanese]. Jpn J Antibiot. 1993;46:159-63.
126. Gall S, Hemsell DL, McGregor JA, Martens MG, Pitkin D, Allen S. Tissue penetration of meropenem in patients undergoing gynecologic surgery. Clin Infect Dis. 1997;24(Suppl 2):S178-80.
127. Tsumura R, Ikawa K, Morikawa N, Ikeda K, Shibukawa M, Iida K, et al. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. J Chemother. 2008;20:615-21.
128. Nau R, Lassek C, Kinzig-Schippers M, Thiel A, Prange HW, Sorgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother. 1998;42:2012-6.
129. Laethem T, De Lepeleire I, McCrea J, Zhang J, Majumdar A, Musson D, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother. 2003;47:1439-42.
130. Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother. 2006;58:632-6.
131. Arrigucci S, Garcea A, Fallani S, Cassetta MI, Canonico G, Tonelli F, et al. Ertapenem peritoneal fluid concentrations in adult surgical patients. Int J Antimicrob Agents. 2009;33:371-3.
132. Wittau M, Wagner E, Kaever V, Koal T, Henne-Bruns D, Isenmann R. Intraabdominal tissue concentration of ertapenem. J Antimicrob Chemother. 2006;57:312-6.
133. Burkhardt O, Majcher-Peszynska J, Borner K, Mundkowski R, Drewelow B, Derendorf H, et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol. 2005;45:659-65.
134. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32:2059-62.
135. Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, Allaouchiche B. Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother. 2007;60:893-6.
136. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother. 2007;60:1395-7.
137. Yamada Y, Ikawa K, Nakamura K, Mitsui K, Narushima M, Hibi H, et al. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients. Int J Antimicrob Agents. 2010;35:504-6.
138. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically Ill patients. Antimicrob Agents Chemother. 2005;49:2421-8.
139. Vos MC, Vincent HH, Yzerman EP. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med. 1992;18:282-5.
140. Thalhammer F. Meropenem and continuous renal replacement. Crit Care Med. 2001;29:1653-4.
141. Valtonen M, Tiula E, Backman JT, Neuvonen PJ. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000;45:701-4.
142. Thalhammer F, Schenk P, Burgmann H, El Menyawi I, Hollenstein UM, Rosenkranz AR, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1998;42: 2417-20.
143. Stevenson JM, Patel JH, Churchwell MD, Vilay AM, Depestel DD, Sorgel F, et al. Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs. 2008;31:1027-34.
144. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009;49:291-8.
145. Hidaka S, Goto K, Hagiwara S, Iwasaka H, Noguchi T. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi. 2010;130:87-94.
146. Cirillo I, Vaccaro N, Evans R, Redman R. Pharmacokinetics of doripenem in chronic hemodialysis subjects during continuous renal replacement therapy (Crrt) [Abstract No A1-106 Plus Poster]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 September 12-15, San Francisco, CA, USA.
147. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase Iii trial. Ann Surg. 2003;237:235-45.
148. Dela Pena AS, Asperger W, Kockerling F, Raz R, Kafka R, Warren B, et al. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg. 2006;10:567-74.
149. Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt). 2007;8:15-28.
150. Yellin AE, Hassett JM, Fernandez A, Geib J, Adeyi B, Woods GL, et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents. 2002;20:165-73.
151. Navarro NS, Jr, Campos MI, Alvarado R, Quintero N, Branicki FJ, Wei J, et al. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int J Surg. 2005;3:25-34.